BullFrog AI appoints Josh Blacher as CFO, following the passing of former CFO Dane Saglio.
Quiver AI Summary
BullFrog AI Holdings, Inc. has announced the appointment of Josh Blacher as Chief Financial Officer following the passing of former CFO Dane Saglio. CEO Vin Singh expressed gratitude for Saglio's contributions and highlighted Blacher's extensive experience in financial strategy and corporate governance, important for carrying on Saglio's legacy. Blacher, who has over 20 years of experience in strategic finance within the life sciences and biotech sectors, previously served as CFO for several companies and has held senior positions at Teva Pharmaceuticals. In his new role, Blacher will focus on strengthening the company's financial operations and supporting its strategic initiatives.
Potential Positives
- Appointment of Josh Blacher as Chief Financial Officer, bringing over two decades of experience in strategic finance and corporate development for life sciences and biotech companies.
- Mr. Blacher's expertise in financial stewardship, operations, and capital raising is expected to enhance the company's balance sheet strength and support its strategic initiatives.
- The press release acknowledges the contributions of former CFO Dane Saglio, creating a narrative of continuity in leadership amidst the transition.
Potential Negatives
- The press release highlights the untimely passing of the former CFO, which could raise concerns about the company's stability and the impact of leadership changes on its operations.
- The need to appoint a new CFO at this moment may indicate potential issues related to financial governance and continuity in leadership.
- The mention of forward-looking statements contains caveats about risks and uncertainties, suggesting potential challenges in achieving the company's projected performance and growth metrics.
FAQ
Who has been appointed as the new CFO of BullFrog AI?
Josh Blacher has been appointed as the Chief Financial Officer of BullFrog AI, effective immediately.
What experience does Josh Blacher bring to BullFrog AI?
Josh Blacher brings over two decades of experience in strategic finance and corporate development within the life science and biotech sectors.
What position did Dane Saglio hold at BullFrog AI before his passing?
Dane Saglio served as the Chief Financial Officer (CFO) of BullFrog AI prior to his untimely passing.
How does BullFrog AI utilize artificial intelligence in drug development?
BullFrog AI employs causal AI and its proprietary bfLEAP platform to analyze complex biological data for improving drug discovery and development.
What is the mission of BullFrog AI?
The mission of BullFrog AI is to revolutionize drug development and reduce failure rates in clinical trials through innovative technology.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BFRG Hedge Fund Activity
We have seen 1 institutional investors add shares of $BFRG stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VIRTU FINANCIAL LLC removed 27,189 shares (-100.0%) from their portfolio in Q3 2024
- RENAISSANCE TECHNOLOGIES LLC removed 19,800 shares (-100.0%) from their portfolio in Q3 2024
- XTX TOPCO LTD removed 8,263 shares (-44.5%) from their portfolio in Q3 2024
- GEODE CAPITAL MANAGEMENT, LLC added 8,221 shares (+29.6%) to their portfolio in Q3 2024
- TOWER RESEARCH CAPITAL LLC (TRC) removed 5,270 shares (-85.6%) from their portfolio in Q3 2024
- UBS GROUP AG removed 3,515 shares (-100.0%) from their portfolio in Q3 2024
- FORTEM FINANCIAL GROUP, LLC removed 1,900 shares (-3.6%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Josh Blacher as its Chief Financial Officer (CFO), effective immediately. This appointment comes in the wake of the untimely passing of Dane Saglio, BullFrog AI's former CFO, who recently lost his battle with cancer.
"Dane's contributions to BullFrog AI were immeasurable. Beyond his exceptional expertise and dedication, Dane was a trusted advisor and a cherished friend. His wisdom, humility, and steadfast commitment to our mission will be deeply missed," said Vin Singh, CEO of BullFrog AI. "At the same time, we are grateful to welcome Josh to our team at this pivotal moment. Josh's extensive experience and leadership in financial strategy and corporate governance will be invaluable as we carry forward Dane's legacy and advance our mission to revolutionize drug development."
Mr. Blacher, with more than two decades of experience in strategic finance and corporate development for life science and biotech companies, brings to BullFrog AI a proven track record in financial stewardship, capital raising, operations and profitability, and deal making. He has successfully overseen SEC reporting and investor relations for both private and publicly traded companies. Most recently, he has served as CFO for Predictive Oncology, Rampart Bioscience, Excision BioTherapeutics, and has previously held senior roles at Teva Pharmaceuticals, among others. Mr. Blacher earned his BA in Economics from Yeshiva University and an MBA in Finance from Columbia Business School.
In assuming the role of CFO, Mr. Blacher will build on the foundation laid by Mr. Saglio, focusing on enhancing the Company's balance sheet strength, financial operations and supporting its strategic initiatives.
About BullFrog AI
BullFrog AI leverages artificial intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.
For more information visit BullFrog AI at:
.
Safe Harbor Statement
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "could," "will," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BFRG@redchip.com
